Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. Luke JJ, et al. Nat Med. 2023 Nov;29(11):2814-2824. doi: 10.1038/s41591-023-02593-0. Epub 2023 Oct 19. Nat Med. 2023. PMID: 37857711 Free PMC article. Clinical Trial.
Druggable genomic landscapes of high-grade gliomas.
Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J; Johns Hopkins Molecular Tumor Board Investigators; Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Ghanem P, et al. Front Med (Lausanne). 2023 Dec 8;10:1254955. doi: 10.3389/fmed.2023.1254955. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38143440 Free PMC article.
Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C.
Godet I, Oza HH, Shi Y, Joe NS, Weinstein AG, Johnson J, Considine M, Talluri S, Zhang J, Xu R, Doctorman S, Mbulaiteye D, Stein-O'Brien G, Kagohara LT, Santa-Maria CA, Fertig EJ, Gilkes DM. Godet I, et al. Among authors: santa maria ca. Nat Commun. 2024 Sep 28;15(1):8416. doi: 10.1038/s41467-024-51995-2. Nat Commun. 2024. PMID: 39341835 Free PMC article.
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.
Shah AN, Santa-Maria CA, Mukhija D, Shah N, Kang AK, Kumthekar P, Burdett K, Chandra S, Chang J, Tsarwhas D, Woodman J, Jovanovic B, Gerratana L, Gradishar W, Cristofanilli M. Shah AN, et al. Clin Breast Cancer. 2023 Apr;23(3):324-329. doi: 10.1016/j.clbc.2022.12.006. Epub 2022 Dec 15. Clin Breast Cancer. 2023. PMID: 36621430 Clinical Trial.
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.
Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Rimawi MF, Krop IE, Lin NU. Freedman RA, et al. Among authors: santa maria ca. Ann Oncol. 2024 Nov;35(11):993-1002. doi: 10.1016/j.annonc.2024.07.245. Epub 2024 Jul 6. Ann Oncol. 2024. PMID: 38977064 Free article. Clinical Trial.
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, Santa-Maria CA, An H, Gonzalez-Ericsson PI, Sanders ME, Newsom KC, Abramson RG, Sheng Q, Hsu CY, Shyr Y, Wolff AC, Pietenpol JA. Lehmann BD, et al. Among authors: santa maria ca. JAMA Oncol. 2024 Feb 1;10(2):193-201. doi: 10.1001/jamaoncol.2023.5424. JAMA Oncol. 2024. PMID: 38095878 Free PMC article.
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. Tolaney SM, et al. Among authors: santa maria ca. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. Future Oncol. 2024. PMID: 38922307 Free PMC article.
74 results